New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria
Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine, resulting in the formation of recurring cystine kidney stones. According to Retrophin, these new tablets are expected to be available in July 2019…